Saturday’s Daily Piece: Updated Guidelines for Diabetes Management in Chronic Kidney Disease

The Kidney Disease: Improving Global Outcomes (KDIGO) organization has released new guidelines for management of diabetes in chronic kidney disease. These guidelines take a multidisciplinary approach. Below are a few medication highlights of the 12 recommendations as well as a link with all of the recommendations.

  1. Treatment with an angiotension-converting enzyme inhibitor (ACEI) or angiotension II receptor blocker (ARB) to be initiated in person with diabetes, hypertension and albuminuria, and titrate to highest approved dose that is tolerated.
  2. Advising persons with diabetes who use tobacco to quit using tobacco products.
  3. Treating persons with type 2 diabetes, CKD and eGFR >/= 30 mL/min/1.73 m2 with metformin.
  4. Treating persons with type 2 diabetes, CKD and eGFR >/= 30 mL/min/1.73 m2 with SGLT2-inhibitor.
  5. In persons with type 2 diabetes and CKD who have not achieve their goal glycemic targets on metformin and SGLT2-inhibitor or are unable to tolerate these medications, a long acting GLP-1 receptor agonist is recommended.

https://www.acpjournals.org/doi/10.7326/M20-5938

DIABETES AND KIDNEY DISEASE – Southwest Florida's Health and Wellness  Magazine
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#diabetes #kidney #medications

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Leave a Reply

Your email address will not be published. Required fields are marked *